Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Upstream Bio, Inc.

NASDAQ: UPB · Life Sciences · 2 alerts · CIK 2022626

Share price
$2.15Close, Nov 16
Market cap
$118M
Shares outstanding
54.81MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Upstream Bio, Inc. filings on SEC EDGAR ↗

7:11 AM ET 10-Q
Financial Results

Upstream Bio Q3 2026 Results: Net Loss of $41.2M, Loss Widens

Upstream Bio reported a net loss of $121.5 million for the nine months ended September 30, 2026, compared to $101.0 million in the prior year, driven primarily by increased research and development expenses for its lead candidate, verekitug. The company's cash, cash equivalents, and short-term investments totaled $207.4 million as of September 30, 2026, down from $341.5 million at the end of 2025.

Key figure
Net loss $41.2M
7:05 AM ET 8-K
Financial Results

Upstream Bio Financial Results

Upstream Bio reported third quarter 2026 financial results, ending the period with $207.4 million in cash and short-term investments. The company is preparing to initiate Phase 3 trials for its lead candidate verekitug in severe asthma and CRSwNP in the first quarter of 2027. Research and development expenses increased to $36.6 million as the company advances its clinical programs and expands its personnel.

Term
Q3 2026

“Our team is focused on the timely execution of startup activities for verekitug’s Phase 3 trials in severe asthma and CRSwNP. Preparations for the planned initiation of these trials in the first quarter of 2027 are well underway, with key clinical, regulatory, and manufacturing milestones now having been achieved.”

Rand Sutherland, MD, Chief Executive Officer of Upstream Bio

“As we look ahead, we remain focused on advancing verekitug in diseases with significant remaining unmet medical need, where we believe its compelling efficacy profile and convenient quarterly at-home dosing have the opportunity to meaningfully redefine treatment expectations and establish a new standard of care.”

Rand Sutherland, MD, Chief Executive Officer of Upstream Bio

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.